US-based medical device contract research organization (CRO) NAMSA is set to acquire the medical device testing business in the US of China-based Contract Development and Manufacturing Organization (CDMO) WuXi AppTec Co., Ltd (SHA: 603259). The acquisition includes two factories located in Minnesota and Georgia. According to the agreement, for which no financial details were disclosed, the two companies will work closely together to ensure a smooth transition for employees and customers.
WuXi AppTec’s Asset Divestiture
WuXi AppTec has been actively divesting its overseas assets. This includes the sale of WuXi Advanced Therapies to Altaris for USD 500 million and the divesture of a 7.17% stake in WuXi XDC Cayman Inc. (HKG: 2268) for HKD 2.426 billion (USD 311.7 million). These moves are part of WuXi AppTec’s broader strategy to optimize its global operations and focus on core business areas.
Implications and Future Outlook
The acquisition by NAMSA highlights the ongoing consolidation and strategic realignment in the medical device testing sector. As NAMSA integrates WuXi AppTec’s US operations, the move is expected to enhance NAMSA’s capabilities and market presence, while WuXi AppTec continues its strategic focus on core strengths and global expansion.-Fineline Info & Tech
Leave a Reply